Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study
Idanna Innocenti(Università Cattolica del Sacro Cuore), Luca Laurenti(Sapienza University of Rome), Elsa Pennese(Ospedale Vito Fazzi), Alessandra Tedeschi(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Robin Foà(Sapienza University of Rome), Livio Trentin(University of Padua), Massimo Gentile(Azienda Ospedaliera di Cosenza), Marina Motta(Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia), Francesca Romana Mauro(Sapienza University of Rome), Daniela Di Sevo(Fondazione Gimema Onlus), Giovanni Del Poeta(University of Rome Tor Vergata), Marina Deodato(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Francesco Autore(Agostino Gemelli University Polyclinic), Lydia Scarfò(IRCCS Ospedale San Raffaele), Ramona Cassin(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Marta Coscia(University of Turin), Alfonso Piciocchi(Fondazione Gimema Onlus), Andrea Visentin(University of Padua), Arianna Rughini(Fondazione Gimema Onlus), Roberta Murru, Antonio Cuneo(Arcispedale Sant'Anna), Anna Maria Frustaci(Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda), Francesca Maria Quaglia(University of Verona), Francesco Albano(University of Bari Aldo Moro), Maurizio Pompili, Paolo Ghia(Vita-Salute San Raffaele University), Claudia Ielo(Policlinico Umberto I), Annamaria Tomasso(Università Cattolica del Sacro Cuore), Valentina Arena(Fondazione Gimema Onlus)
Cited by 20
Related Papers
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890